

The first Oral broad spectrum anti-fungal.



NEW

Nizoral
(ketoconazole)

trademark

Superficial Fungal Infections.

NIZORAL* is a new Oral anti-fungal agent effective against both dermatophyte and yeast infection of the skin and scalp.

Recurrent Vaginal Candidosis.

NIZORAL* offers a simple, effective Oral therapy to aid patient compliance.

Systemic Fungal Infections.

NIZORAL* is a uniquely convenient and well tolerated treatment. It is also effective in prophylaxis for immuno-compromised patients.

PRESCRIBING INFORMATION: Presentation White, flat, half scored uncoated tablets marked 'JANSSEN' on the reverse. Each contains ketoconazole 200mg. **Uses** Nizoral* is an orally active antimycotic for the treatment, in adults, of superficial and systemic mycoses including dermatophyte and yeast infection of the skin and hair, yeast infection of the mouth and G.I. tract, recurrent or chronic vaginal candidosis not responding to topical treatment. Also maintenance treatment in systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in 'at risk' patients. In children: systemic mycoses and severe local infection where previous topical treatment has failed. **Side-effects, Precautions, Contra-indications** Contra-indicated in pregnancy. For optimum absorption, Nizoral* should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H₂ blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral*. Nausea, skin rash, occasionally observed. **Dosage** Adults: superficial and systemic mycoses, prophylactic treatment - 200mg once daily increased to 400mg daily if required: vaginal candidosis - 200mg morning and evening for 5 days. Children: 50 or 100mg depending on bodyweight (approximately 3mg/kg). **Product Licence No.** PL 0242/0083. **Basic NHS Cost** 10 tablets £4.90. 30 tablets £14.26 (correct at time of printing).

Further information is available from  Janssen Pharmaceutical Limited, Janssen House, Chapel Street, Marlow, Bucks. SL7 1ET.

*Trademark

STATISTICS AT SQUARE ONE

by T. D. V. SWINSCOW

from the British Medical Journal


The statistical testing of data is indispensable in many types of medical investigation and a help on countless occasions in clinical practice. This book provides step-by-step instruction. Subjects covered include standard deviation, χ^2 tests, t tests, non-parametric tests and correlation. Methods specially adapted to pocket calculators.

"The ability to put symbols in sequence may well be one of the greatest advances in man's development. . . . This excellent and attractive volume will give you an idea into which category an article or projected article fits. The ink you save may be your own. It is superb value."

O'Donnell, Barry, *British Medical Journal*, 1977, 1, 451.

"... this gem of a practical booklet squeezes the essence of biostatistics into 75 well-written, well-organized pages. Newcomers to the field will like the way obscure concepts are clarified; experts will find the book valuable as a teaching aid."

de Jong, Rudolph H., *J.A.M.A.*, 1977, 237, 1874



Seventh edition


**PRICE: Inland £2.50
Overseas US\$10.00,
including despatch by
Air Mail**

*Payment must be enclosed with
order or a surcharge of 50p will
be made for rendering invoices
and statements*

ORDER YOUR COPY NOW

*From: The Publisher,
British Medical Journal,
BMA House,
Tavistock Square,
London WC1H 9JR*

or through any leading bookseller



Septrin Assurance

Prescribing Information

Indications Sensitive bacterial infections of the lower respiratory, urinary and genital tracts, sinusitis, otitis media, skin infections, septicaemia, typhoid and paratyphoid fevers, and other infections caused by sensitive organisms.

Dosage Septrin Forte Tablets. Adults and children over 12 years: 1 forte tablet twice daily. Maximum dosage for particularly severe infections 1½ forte tablets twice daily. In acute infections Septrin should be given for a minimum of five days or until the patient has been symptom-free for two days.

Contra-indications Septrin is contra-indicated in

patients with marked liver parenchymal damage, blood dyscrasias or severe renal insufficiency. Septrin should not be given to patients hypersensitive to sulphonamides, trimethoprim or co-trimoxazole; should not be given during pregnancy or to neonates.

Precautions In renal impairment a reduced dosage is indicated and an adequate urinary output should be maintained. Regular blood counts are necessary whenever long-term therapy is used. Caution is advised in patients with folate deficiency. Care should be taken when giving Septrin to patients receiving oral anticoagulants of the coumarin group, pyrimethamine or sulphonylureas.

Adverse Reactions Occasionally, nausea, vomiting, glossitis and skin rashes may occur with normal doses and, very rarely, haematological reactions.

Presentation Septrin Forte Tablets each contain 160 mg Trimethoprim BP and 800 mg Sulphamethoxazole BP. PL3/0121.

Septrin* Forte 1b.d. co-trimoxazole

Further information is available on request.
Wellcome Medical Division
The Wellcome Foundation Ltd., Crewe, Cheshire



*Trade Mark

British Council Medical Courses

PERINATAL PAEDIATRICS

(Dr D Harvey and Dr D Baum)

20 June-2 July 1982 in London and Oxford

Fee: £580 (Residential), £340 (Non-residential)

CHILD MENTAL HEALTH AND PSYCHOSOCIAL DEVELOPMENT

(Professor P J Graham)

11-23 July 1982 in London

Fee: £495 (Residential), £290 (Non-residential)

PSYCHOGERIATRICS

(Professor T H D Arie)

11-23 July 1982 in Nottingham

Fee: £550 (Residential), £325 (Non-residential)

COMPUTING IN MEDICAL MICROBIOLOGY

(Dr G Frency and Professor I Phillips)

18-28 July 1982 in London

Fee: £585 (Residential), £340 (Non-residential)

MODERN OBSTETRICS AND GYNAECOLOGY

(Mr Geoffrey Chamberlain)

12-24 September 1982 in London

Fee: £632 (Residential), £392 (Non-residential)

THE AGEING OF POPULATIONS: CLINICAL CARE OF THE ELDERLY

(Professor J Williamson and Dr R G Smith)

12-24 September 1982 in Edinburgh

Fee: £460 (Residential), £350 (Non-residential)

NEW APPROACHES TO DERMATOLOGICAL THERAPY

(Professor M W Greaves and Dr A Griffiths)

12-24 September 1982 in London

Fee: £595 (Residential), £345 (Non-residential)

THE CHILD AND INFECTION

(Dr W C Marshall and Dr W A M Cutting)

19 September-1 October 1982 in London

Fee: £525 (Residential), £325 (Non-residential)

CLINICAL AND DIAGNOSTIC VIROLOGY

(Dr T H Flewett)

7-19 November 1982 in Birmingham

Fee: to be announced

BLOOD TRANSFUSION

(Dr J D Cash)

14-26 November 1982 in London

Fee: £525 (Residential), £305 (Non-residential)

EXPANDING HORIZONS OF DIAGNOSTIC ULTRASOUND

(Dr P N T Wells, Dr Hylton Meire and

Dr J P Woodcock)

14-26 November 1982 in Bristol

Fee: £635 (Residential), £370 (Non-residential)

CLINICAL MEDICINE OF OLD AGE

(Professor A N Exton-Smith and Dr W Davidson)

13-25 March 1983 in Cambridge

Fee: to be announced

RECENT ADVANCES IN RENAL MEDICINE

(Dr R Wilkinson)

13-25 March 1983 in Newcastle

Fee: to be announced

RECENT ADVANCES IN MEDICAL IMMUNOLOGY

(Professor D C Dumonde)

14-26 March 1983 in London

Fee: to be announced

MALIGNANT DISEASE IN CHILDHOOD

(Professor R M Hardisty)

8-20 May 1983 in London

Fee: to be announced

NUTRITION AND GROWTH

(Dr J T Harries and Dr W P T James)

26 June-8 July 1983 in London and Cambridge

Fee: to be announced

TUBERCULOSIS

(Professor W Fox and Professor Mitchison)

18-30 September 1983 in London

Fee: to be announced

SCIENTIFIC BASIS OF HAEMOSTASIS AND THROMBOSIS

(Professor V V Kakkar)

9-20 October 1983 in London

Fee: to be announced

Names of Directors of Studies are shown in brackets.

FURTHER INFORMATION AND APPLICATION FORMS CAN BE OBTAINED FROM YOUR LOCAL OVERSEAS REPRESENTATIVES OF THE BRITISH COUNCIL OR FROM COURSES DEPARTMENT, PUBLICITY AND RECRUITMENT SECTION, THE BRITISH COUNCIL, 65 DAVIES STREET, LONDON W1Y 2AA.



Behind the
gentleness of

Burinex K

bumetanide and slow release potassium chloride

lies the power of

Burinex

Burinex K
gently effective
for maintenance

Burinex tablets

combine strength with

gentleness for more refractory oedema

Burinex injection

fast powerful action for emergencies

Pharmaceuticals: Burinex Injection: 0.5 mg/ml in 2 ml, 4 ml and 10 ml ampoules. Burinex Tablets: 1 mg and 5 mg. Burinex K: 0.5 mg bumetanide, 7.7 mmol slow release potassium chloride. Indications: Acute pulmonary oedema and oedema of cardiac, renal or hepatic origin. Dosages: Burinex Injection: Initially 1-2 mg i.v., if necessary repeated at 30 minute intervals to achieve desired response. Where appropriate higher doses may be given by infusion over 30-60 minutes. Burinex K: 1 mg tablets require 1 mg Burinex daily as morning or evening dose. In refractory cases dosage can be increased to achieve the desired response. For high dose treatment 5 mg Burinex should be given initially followed by 1 mg every 12-24 hours until desired response is achieved. Burinex K: Most patients require 2 tablets Burinex K daily. Contra-indications: Exacerbation and Side Effects: Contra-indicated in hepatic coma, severe renal impairment, severe congestive heart failure. Hypotensive and circulatory collapse may occur. Caution should be exercised in the first 24 hours of treatment. Burinex K is contra-indicated in combination with potassium sparing agents. Burinex K should be stopped immediately if signs or symptoms of bowel obstruction appear. Side effects such as skin rashes, gastroenteric upset, raised serum uric acid and thrombocytopenia may rarely occur. Product Licence Numbers: Burinex Injection: 0043/0021, 0043/0043 Burinex K: 0043/0022, 0043/0043. Price: Burinex Injection: 0.5 mg/ml - 5 x 4 ml £3.26 Burinex Tablets: 1 mg - 100 tabs £8.74, Burinex K: 100 tabs £3.24



*Burinex is a trade mark

Leo Laboratories Limited, 15 Grosvenor Road, Princes Risborough, Aylesbury Bucks, HP17 9RR